Variation in health-related quality of life (HRQOL) by ECOG performance status (PS) and fatigue among patients with chronic lymphocytic leukemia (CLL).
Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Ren Yu(Health Outcomes Solutions (United States)), Mark A. Weiss(Thomas Jefferson University), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), David L. Grinblatt(NorthShore University HealthSystem), Mark Kozloff(Ingalls Memorial Hospital), Chris L. Pashos(Oldham Council), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Susan Lerner(Molecular Templates (United States)), Thomas J. Kipps(University of California San Diego), Charles M. Farber(Morristown Medical Center), Thomas K. Street(Bristol-Myers Squibb (Switzerland)), Arlene S. Swern, Kristen Sullivan(Tufts University), Ian W. Flinn(Tennessee Oncology), Zeba M. Khan(Bristol-Myers Squibb (Switzerland)), Neil E. Kay(Mayo Clinic)
Cited by 3
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k